Dr. Marlowe received his BS in Pharmacology and Toxicology from the State University of New York at Buffalo and then subsequently obtained his PhD in Molecular Pharmacology and Cancer Therapeutics at Roswell Park Cancer Institute. His previous work focused on the discovery of small molecule kinase inhibitors, as well as the identification of novel protein-protein interactions. Dr. Marlowe has a strong background in pharmacology and drug discovery, with major expertise in structure-based drug design, computational drug discovery and a wide variety of biophysical/biochemical assays. His current focus is the utilization of Surface Plasmon Resonance (SPR), Nuclear Magnetic Resonance (NMR) and X-ray Crystallography techniques for Fragment-based Drug Discovery (FBDD) and peptidomimetics. Dr. Marlowe is the director of the Molecular Analysis Core at the University of Arizona (UA) College of Medicine – Phoenix, where he helps facilitate the study of biomolecular interactions. He also directs an academic drug discovery laboratory along with William Cance, MD, at the UA Cancer Center at Dignity Health St. Joseph's Hospital and Medical Center, where the main focus is the discovery of novel small molecules that target Focal Adhesion Kinase (FAK). Dr. Marlowe is a member of the UA spin-off company FAKnostics, LLC. Furthermore, Dr. Marlowe is a research assistant professor at the UA College of Pharmacy and College of Medicine – Phoenix, where he contributes to research projects, teaching and grant writing.